MSU
ICPT

Maple Securities USA’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Maple Securities USA’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,815
Closed -$438K – 198
2015
Q2 		$438K Buy
+1,815
New +$483K 0.04% 146
2014
Q3 		– Sell
-1,947
Closed -$461K – 325
2014
Q2 		$461K Buy
1,947
+374
+24% +$98.6K 0.05% 92
2014
Q1 		$519K Buy
+1,573
New +$531K 0.05% 80

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Maple Securities USA's ICPT Position: Q3 2015 in Review

Maple Securities USA sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2015, closing a stake of 1,815 shares — an estimated $438K sold.

Maple Securities USA first reported a position in ICPT in Q1 2014 and held it in 3 quarters. The position peaked at $519K in Q1 2014. 173 funds tracked by Wall St. Rank hold ICPT as of Q3 2015.

  • Maple Securities USA reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Maple Securities USA sold 1,815 Intercept Pharmaceuticals, Inc. shares in Q3 2015, an estimated $438K.
  • Maple Securities USA first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 3 quarters.
  • Maple Securities USA's Intercept Pharmaceuticals, Inc. position peaked at $519K in Q1 2014.
  • 173 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2015.

Based on Maple Securities USA's 13F filing for Q3 2015, filed 3 Nov 2015.